Should aprotinin continue to be used during cardiac surgery? Commentary

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 7, 2006, Pages 360-361

  Levy, Jerrold H ^a   Despotis, George J ^b   Spitznagel, Edward ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aminocaproic acid; Antifibrinolytic therapy; Aprotinin; Cardiac surgery; Tranexamic acid

Indexed keywords

AMINOCAPROIC ACID; APROTININ; TRANEXAMIC ACID;

ANTICOAGULANT THERAPY; CARDIOPULMONARY BYPASS; CARDIOVASCULAR SURGERY; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ECG ABNORMALITY; HEART FAILURE; HEART INFARCTION; HEART OUTPUT; HUMAN; INTERVIEW; KIDNEY DYSFUNCTION; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; ST SEGMENT;

EID: 33745520392     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0578     Document Type: Short Survey

References (5)

1. D'Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17: 2265-2281
2. Byar DP (1991) Problems with using observational databases to compare treatments. Stat Med 10: 663-666
3. Karkouti K et al. (2005) Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. J Thorac Cardiovasc Surg 129: 391-400
4. Wijeysundera DN et al. (2006) Improving the identification of patients at risk of postoperative renal failure after cardiac surgery. Anesthesiology 104: 65-72
5. Kincaid EH et al. (2005) Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann Thorac Surg 80: 1388-1393